Inspire Medical Systems, Inc. (NYSE:INSP ) Q4 2024 Earnings Conference Call February 10, 2025 5:00 PM ET Company Participants Ezgi Yagci - Vice President of Investor Relations Tim Herbert - President & Chief Executive Officer Rick Buchholz - Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Securities Danielle Antalffy - UBS Robbie Marcus - JPMorgan Chris Pasquale - Nephron Research Anthony Petrone - Mizuho Financial Group Richard Newitter - Truist Securities David Rescott - Baird Adam Maeder - Piper Sandler Larry Biegelsen - Wells Fargo Shagun Singh - RBC Capital Markets Brett Fishbin - KeyBanc Capital Markets Jon Block - Stifel Michael Polark - Wolfe Research Mike Kratky - Leerink Partners Suraj Kalia - Oppenheimer & Co. Operator Good afternoon. My name is Dilem [ph] and I'll be your conference operator today.
Inspire Medical Systems (INSP -0.64%), known for its innovative devices that use neurostimulation to treat sleep apnea, announced impressive fourth-quarter results on Feb. 10. Earnings per share (EPS) came in at $1.15, well ahead of the $0.73 consensus estimate.
Although the revenue and EPS for Inspire (INSP) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Inspire Medical Systems (INSP) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.49 per share a year ago.
Beyond analysts' top -and-bottom-line estimates for Inspire (INSP), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
INSP's revenue growth in the fourth quarter is likely to have been boosted by increased market penetration in existing centers and expansion into new implanting centers.
BofA Securities has upgraded Inspire Medical Systems, Inc. INSP and says the company now falls in the profitable growth category.
Inspire Medical's both geographic segments witness strong revenue growth on the back of solid product demand in the third quarter.
Inspire Medical Systems, Inc. (NYSE:INSP ) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Ezgi Yagci – Vice President-Investor Relations Tim Herbert – President and Chief Executive Officer Rick Buchholz – Chief Financial Officer Conference Call Participants Robbie Marcus – JPMorgan Danielle Antalffy – UBS Travis Steed – Bank of America Securities Adam Maeder – Piper Sandler David Rescott – Baird Michael Sarcone – Jefferies Richard Newitter – Truist Securities Larry Biegelsen – Wells Fargo Shagun Singh – RBC Kallum Titchmarsh – Morgan Stanley Jon Block – Stifel Anthony Petrone – Mizuho Americas Brett Fishbin – KeyBanc Capital Markets Chris Pasquale – Nephron Research Michael Polark – Wolfe Research Mike Kratky – Leerink Partners Suraj Kalia – Oppenheimer & Co Operator Good afternoon. My name is Dilem, and I'll be your conference operator today.
Although the revenue and EPS for Inspire (INSP) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.